Spherix Global Insights Launches Obesity Franchise to Connect Research Across Specialties

Exton, PA, Oct. 05, 2026 /CourierPR/ -- Spherix Global Insights, an independent market intelligence and advisory firm serving the global life sciences industry, has launched a new Obesity Franchise to better connect its existing obesity research with expertise in gastroenterology and nephrology. This move aims to expand the firm’s publication portfolio and advisory capabilities as treatment decisions increasingly span obesity, cardiometabolic health, and kidney disease.

The Obesity Franchise will focus on the intersection of obesity with MASH (Mental, Addiction, and Sexual Health) and CKD-ND (Chronic Kidney Disease-Non-Dialysis) conditions. By integrating research from various perspectives, including physician, patient, and payer, the franchise will help clients understand the complexities of therapy adoption, treatment burden, and formulary decisions. This integrated view will support organizations in navigating the cardiovascular-kidney-metabolic (CKM) framework.

The Obesity Franchise will leverage Spherix’s established Nephrology Franchise, led by Kari McCarthy. Together, these franchises will provide a broader view of how weight management is influencing treatment strategies across interconnected metabolic, cardiovascular, and kidney diseases. Research titles will examine challenges in treating patients with non-dialysis chronic kidney disease (CKD-ND) and cardiorenal disease, including treatment patterns, unmet needs, and the clinical and access dynamics shaping adoption.

Spherix’s Obesity Franchise will offer syndicated intelligence and tailored advisory support for development, launch, positioning, and market access decisions. Clients can draw on therapeutic expertise and research tailored to specific strategic questions, from understanding prescribing patterns to identifying barriers to treatment adoption and continuity. The firm’s established KOL synthesis, trusted by 19 of the top 20 pharmaceutical and biotech organizations, will play a crucial role in providing clients with a clearer understanding of the market.

Establishing the Obesity Franchise will give clients a clearer point of access to Spherix’s research and specialists while positioning the firm to deepen its coverage of an increasingly interconnected area of care. By connecting Spherix’s obesity research with its gastroenterology and nephrology expertise, the firm aims to provide clients with a comprehensive view of the evolving landscape of obesity and related conditions.

This expansion reflects Spherix’s commitment to staying at the forefront of market intelligence and advisory services for specialty pharmaceutical and biotech markets. By offering a focused and integrated approach, the Obesity Franchise will help clients navigate the complexities of obesity and related conditions, ensuring they can make informed decisions in a rapidly evolving healthcare landscape.